| abstract |
Also provided are pharmaceutical compositions comprising compounds of the formula (1), as well as methods for treating viral infections using compounds of the formula (1). Claim 1: A compound represented by the formula (1), or its pharmaceutically acceptable salt, characterized in that: L¹, L², L³, L⁴, L⁵, and L⁶, each independently, are a bond or a connector of -C (R conector ) ₂-O-; R⁰, independently for each occurrence, is H or C₁₋₆ alkyl; R¹, R², and R³, each independently, are selected from the group consisting of H, aminoacyl, aminothionyl, acyl, R¹⁰OC (O) -, phosphoryl and aminophosphoryl; R¹ and R², taken together, or R² and R³, taken together, are selected from the group consisting of carbonyl, thiocarbonyl, phosphoryl and C₁₋₆phosphoryl alkyl; R⁴, R⁵, and R⁶, each independently, are selected from the group consisting of H, acyl, phosphoryl, alkylthio, R¹⁰OC (O) -, and aminoalkyl; R⁷ is H; or R⁶, R⁷, and the nitrogen to which they are attached, taken together, represent -N = CR²⁰R²¹; R¹⁰, independently for each occurrence, is selected from the group consisting of H, C₁₋₆ alkyl, aryl, heteroaryl, aralkyl and heteroaralkyl; R²⁰ and R²¹, each independently, are selected from the group consisting of H, alkyl, amino, aryl, heteroaryl, aralkyl and heteroaralkyl; provided that the compound represented by the formula (1) is not the compound of the formula (2). |